Mednet Logo
Community

What is your preferred first-line therapy for a patient with standard risk multiple myeloma?

Has the recent data presented at ASH affected your choice of regimen? Would your choice differ between transplant-eligible and transplant-ineligible patients?
Community PollStarted

What is your preferred first-line therapy for a patient with low risk multiple myeloma?

63 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on

Tough question.

Let's do the easy ones first. The low risk (R-ISS 1) fit patient could be treated any number of ways with Bortezomib+Lenalidomide+Dexamethasone (RVd), Carfilzomib+Lenalidomide+Dexamethasone (KRd), or Daratumumab+Lenalidomide+Dexamethasone (Dara-Rd). Bortezomib can lead to neuropathy...

Join for free or sign in to see the full answer